About Oisin Biotechnologies
Oisin Biotechnologies is a private company based in Seattle, Washington. It has reported $18,361,341 raised in four offerings on Form D since February 2020. Its chief executive is Matthew Scholz.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | Jul 12, 2024 | $5,380,000of $17.8M target | 36 | $149K | EquityRule 506(b) | Form D ↗ |
| Jul 24, 2021 | Aug 6, 2021 | $475,000of $5.0M target | 8 | $59,375 | Equity, Options, Securities on exercise, SAFEsRule 506(b) | Form D ↗ |
| Jun 10, 2020 | Jun 23, 2020amended May 28, 2021 | $9,531,365of $9.5M target | 90 | $105K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Dec 19, 2017 | Feb 25, 2020 | $2,974,976of $3.0M target | 48 | $61,979 | OptionsRule 506(b) | Form D ↗ |
| Total, four offerings | $18,361,341 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Oisin Biotechnologies's Form D filed Jul 12, 2024.
EG
Eric Garcia
Executive officer
MS
Matthew Scholz
President & CEO, director
DG
David Gobel
Director
SH
Stephen Hilbert
Executive officer
JL
John Lewis
Executive officer
GH
Gary Hudson
Executive officer and director
DQ
Danjuma Quarless
Director